Bioequivalence clinical trial of two formulations of canagliflozin
Canagliflozin is a medicine commonly prescribed to help manage blood sugar levels in adults with type 2 diabetes. This clinical trial is known as a bioequivalence study. Its main goal is to compare a new formulation of canagliflozin with the standard version already in use. Researchers are looking for healthy adult volunteers to take part. Because participants do not have diabetes or other complex health conditions, doctors can clearly measure how the body absorbs, breaks down, and clears the medicine. Volunteers will take each version of the tablet at different times, and regular blood samples will track medicine levels in the bloodstream. Studies like this are a vital step in licensing new, often more affordable versions of essential medicines. They confirm that the new tablet behaves identically in the body, ensuring patients get the exact same benefits and safety as the original brand.
At a glance
What is this study about?
Canagliflozin is a well-known medicine used to treat type 2 diabetes. It works by helping the kidneys remove extra sugar from the blood through the urine. When a pharmaceutical company develops a new version of an established medicine—such as a generic brand or an updated tablet design—they must prove that it works in the human body in precisely the same way as the original. This trial aims to compare two different tablet formulations of canagliflozin to see if they behave identically.
In medicine, this type of research is called a bioequivalence study. When you swallow a tablet, it dissolves in your stomach, gets absorbed into your bloodstream, and is eventually cleared by your liver and kidneys. A bioequivalence trial carefully measures how quickly the medicine enters the blood and how much of it gets absorbed. If the two tablets produce the same levels in the blood over time, doctors know they can be used interchangeably.
This trial is being carried out with healthy volunteers rather than people living with diabetes. Testing in healthy individuals allows researchers to see the true effects of the tablet without interference from other health conditions or daily diabetes medications. It provides clean, reliable data about how the body handles the medicine.
Running these trials is an essential part of making medicines accessible. When generic versions are proven to be just as reliable as brand-name drugs, it helps healthcare systems like the NHS offer high-quality treatments at a lower cost, ensuring that everyone who needs effective medication can receive it.
Key takeaways
- The trial compares two different tablet versions of canagliflozin to confirm they work the same way.
- It is open to healthy adult volunteers aged 18 and older.
- Volunteers will take single doses of the tablets and have routine blood tests to track medicine levels.
- There is no direct health benefit, but participants help make safe, affordable medicines available.
- Participation is completely voluntary, and you can stop taking part at any time.
Who may be eligible?
This study is open to healthy men and women aged 18 and older. Because this is an early-stage study designed to measure the medicine's behaviour, participants must generally be in good health with no significant ongoing medical conditions.
You are unlikely to be eligible if you have long-term conditions affecting your heart, kidneys, or liver, or if you have a history of diabetes. Women who are pregnant, planning to become pregnant, or breastfeeding will not be able to join for safety reasons. You may also be excluded if you take regular prescription medicines, smoke heavily, or have had recent issues with alcohol or drug misuse.
Before taking part, everyone must complete a full health check. This screening includes a physical examination, blood and urine tests, and a heart tracing (ECG) to make sure it is completely safe for you to take the study medicine.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I consider myself to be in good overall health.
- I do not have type 2 diabetes or kidney problems.
- I am not pregnant or breastfeeding.
- I am not currently taking regular prescription medications.
- I am willing to spend time at a clinical research facility for tests.
What does participation involve?
Taking part in this study usually involves an initial screening visit followed by one or two stays at a specialist clinical research unit. During your visits, you will receive a single dose of canagliflozin with a glass of water. In most trials of this type, you take one version of the tablet first, wait a week or two for it to fully leave your body (a 'washout' period), and then return to take the other version.
While at the clinic, the research team will take regular, small blood samples—often using a tiny plastic tube (cannula) placed in your arm so you do not need multiple needle pricks. These samples allow scientists to measure the exact amount of medicine in your blood over a 24- to 48-hour period. Staff will also check your blood pressure, temperature, and heart rate regularly. The entire study typically lasts between two and four weeks from your first check-up to a final health assessment.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is the purpose of a bioequivalence trial?
It proves that a new or generic version of a tablet delivers the exact same amount of active medicine into the blood at the same speed as the original version.
Do I need to have diabetes to take part?
No. This trial is specifically for healthy volunteers without diabetes to ensure other health factors do not interfere with the test results.
Will taking this medicine lower my blood sugar dangerously?
Canagliflozin rarely causes dangerously low blood sugar on its own in healthy people because it mainly removes extra sugar through urine, but doctors will monitor your sugar levels closely.
Will I be compensated for taking part?
Most Phase I trials with healthy volunteers provide payment to cover travel costs and compensate you for the time spent staying at the clinic.
Can I leave the study if I feel uncomfortable?
Yes. Joining a clinical trial is entirely voluntary, and you have the right to withdraw at any time without any penalty.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.